Omnic, 0.4 mg 10 pcs
€10.50 €9.19
The Omnic is an alpha-adrenolytic.
Pharmacodynamics
Blockade of α1-adrenoreceptors by tamsulosin results in reduction of the tone of the smooth muscles of the prostate, bladder neck and prostatic part of the urethra and improvement of outflow of urine. Simultaneously both symptoms of emptying and symptoms of filling caused by increased tone of smooth muscles and detrusor hyperactivity in benign prostatic hyperplasia are reduced.
The ability of tamsulosin to affect α1A-subtype adrenoreceptors is 20 times greater than its ability to interact with α1B-subtype adrenoreceptors located in vascular smooth muscle. Due to its high selectivity, tamsulosin does not cause clinically significant reduction of systemic BP both in patients with arterial hypertension and in patients with normal baseline BP.
Pharmacokinetics
Absorption
Tamsulosin is well absorbed in the intestine and has almost 100% bioavailability. Absorption of tamsulosin slows down slightly after meals. The same level of absorption can be achieved if the patient takes the drug after the usual breakfast each time. Tamsulosin is characterized by linear kinetics. After a single oral dose of 0.4 mg of the drug, its Cmax in plasma is reached after 6 h. After multiple oral doses of 0.4 mg per day, the equilibrium concentration is reached by day 5, with a value of about 2/3 that after a single dose.
Distribution
The binding to plasma proteins is 99%; the volume of distribution is small (about 0.2 L/kg).
Metabolism
Tamsulosin is slowly metabolized in the liver to form less active metabolites. Most of tamsulosin is present in plasma in unchanged form.
The ability of tamsulosin to slightly induce the activity of microsomal liver enzymes has been revealed in the experiment.
In mild to moderate hepatic insufficiency there is no need to adjust the dosing regimen.
Tamsulosin and its metabolites are primarily excreted in the urine, with about 9% of the drug excreted unchanged.
The T1/2 of the drug is 10 hours with a single administration of 0.4 mg after a meal, and 13 hours with multiple administration.
In case of renal impairment, no dose reduction is required if the patient has severe renal impairment (creatinine Cl
Indications
Dysuric Disorders in Benign Prostatic Hyperplasia (Treatment).
Active ingredient
Composition
Active ingredient:
Tamsulosin hydrochloride 0.4 mg;
Supplementary substances:
MCC;
Methacrylic acid copolymer (type C);
polysorbate 80;
sodium lauryl sulfate;
triacetin;
calcium stearate;
talc;
gelatin;
indigotine;
titanium dioxide;
iron oxide yellow;
iron oxide red
How to take, the dosage
Ingestion. After breakfast with water, 1 capsule (0.4 mg) once daily.
The capsule should not be chewed because this may affect the rate of release of the drug.
Interaction
No interactions have been found with atenolol, enalapril or nifedipine when Omnic® was administered together. When concomitant use of Omnic® with cimetidine, a slight increase in plasma concentration of tamsulosin and a decrease in concentration with furosemide were noted (this does not require changing the dose of Omnic®, since the drug concentration remains within the normal range).
Diazepam, propranololol, trichloromethiazide, chlormadinone, amitriptyline, diclofenac, glibenclamide, simvastatin and warfarin do not alter the free plasma fraction of tamsulosin in vitro. In turn, tamsulosin also does not alter the free fractions of diazepam, propranolol, trichloromethiazide and chlormadinone.
In in vitro studies, no interaction at the level of hepatic metabolism was found with amitriptyline, salbutamol, glibenclamide and finasteride.
Diclofenac and warfarin may increase the excretion rate of tamsulosin.
The concomitant administration of other α1 adrenoreceptor antagonists may decrease BP.
Special Instructions
As with other α1-adreno-blockers, treatment with Omnic® may occasionally cause a decrease in BP, which may sometimes lead to fainting.
At the first signs of orthostatic hypotension (dizziness, weakness) the patient should sit or lie down and stay in this position until the signs disappear. In surgical interventions for cataract the development of intraoperative iris instability syndrome (syndrome of narrow pupil) is possible during the drug administration; the surgeon must take it into account during the preoperative preparation of the patient and during the operation.
Before starting therapy with Omnic®, the patient must be examined to rule out the presence of other conditions that may cause the same symptoms as benign prostatic hyperplasia. A finger rectal examination and, if necessary, a prostate specific antigen (PSA) test should be performed before starting treatment and regularly during therapy.
Contraindications
With caution: severe renal impairment (creatinine Cl
Side effects
Rarely – dizziness, retrograde ejaculation; in single cases – orthostatic hypotension, tachycardia/heart palpitations, asthenia, headache.
Gastrointestinal disorders: rarely – nausea, vomiting, diarrhea, constipation.
In extremely rare cases hypersensitivity reactions (skin rash, itching, angioedema) may be observed.
Overdose
Symptoms:It is theoretically possible to develop an acute decrease in BP and compensatory tachycardia.
Treatment: removal of patient to the horizontal position, gastric lavage, administration of activated charcoal or osmotic laxative (sodium sulfate); if no effect, administration of means increasing the blood pressure, if necessary, vasoconstrictors; symptomatic therapy. Renal function should be monitored. The effectiveness of dialysis is unlikely.
Similarities
Weight | 0.013 kg |
---|---|
Shelf life | 4 years |
Conditions of storage | At a temperature not exceeding 25 °C |
Manufacturer | ZiO-Zdorovye CJSC, Russia |
Medication form | modified-release capsules |
Brand | ZiO-Zdorovye CJSC |
Other forms…
Related products
Buy Omnic, 0.4 mg 10 pcs with delivery to USA, UK, Europe and over 120 other countries.